Quarterly report pursuant to Section 13 or 15(d)

Discontinuing Operations - Summarized results of consolidated discontinued operations (Details)

v3.19.3
Discontinuing Operations - Summarized results of consolidated discontinued operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 01, 2019
Dec. 31, 2018
Income Statement Disclosures            
Revenue $ 428 $ 5,405 $ 10,066 $ 17,400    
Cost of revenues 563 3,969 7,692 12,444    
Gross profit (loss) (135) 1,436 2,374 4,956    
Research and development 47 692 937 2,046    
General and administrative 782 3,065 4,121 9,714    
Sales and marketing 15 960 1,527 3,312    
Restructuring costs 100 1,418 100 2,151    
Transaction costs 0 0 651 0    
Impairment of patents and other intangible assets 601 0 601 0    
Total operating expenses 1,545 6,135 7,937 17,223    
Loss from discontinuing operations (1,680) (4,699) (5,563) (12,267)    
Interest expense (38) (383) (2,211) (1,195)    
Gain on disposal of business 8,496   8,496      
Total other income (expense) 8,458 (383) 6,285 (1,195)    
Net income (loss) from discontinuing operations 6,778 (5,082) 722 (13,462)    
Current assets of discontinuing operations:            
Accounts receivable, net of allowance for doubtful accounts of $3,785 in 2019; $3,462 in 2018 1,082   1,082     $ 6,261
Allowance for doubtful accounts 3,785   3,785     3,462
Other current assets 43   43     1,652
Fixed assets, net of accumulated depreciation 0   0     3,559
Patents and other intangible assets, net of accumulated amortization 0   0     655
Goodwill 0   0     11,294
Current assets of discontinuing operations 1,125   1,125   $ 25,748 23,421
Current liabilities of discontinuing operations            
Accounts payable and accrued expenses 3,229   3,229     9,967
Obligations under finance leases 0   0     666
Deferred revenue 0   0     1,337
Line of credit 0   0     2,621
Term note 0   0     6,000
Deferred rent payable and other 0   0     151
Current liabilities of discontinuing operations 3,229   3,229   $ 23,069 $ 20,742
Clinical Business Disposal            
Income Statement Disclosures            
Gain on disposal of business 1,222 0 1,222 0    
BioPharma Disposal            
Income Statement Disclosures            
Gain on disposal of business 7,274 0 7,274 0    
Current assets of discontinuing operations:            
Accounts receivable, net of allowance for doubtful accounts of $3,785 in 2019; $3,462 in 2018 4,064 0 4,064 0    
Other current assets 1,142 0 1,142 0    
Current liabilities of discontinuing operations            
Obligations under finance leases 423 0 423 0    
Deferred revenue 1,053 0 1,053 0    
Line of credit 2,665 0 2,665 0    
Term note $ 6,000 $ 0 $ 6,000 $ 0